Please login to the form below
Scott Gottlieb
This page shows the latest Scott Gottlieb news and features for those working in and with pharma, biotech and healthcare.
Gilead reports remdesivir cuts risk of death in severe COVID-19 patients
Former US Food and Drug Administration (FDA) commissioner Scott Gottlieb also said that rigorous confirmation is needed to further support the data, tweeting that “this is very encouraging but needs to
Latest news
-
UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
He was also backed by previous FDA commissioner Scott Gottlieb, who endorsed Sharpless as “an outstanding physician and scientist who is deeply committed to public health goals” who he hoped would
-
Mega-mergers dominate as buoyant markets lift biopharma
now former FDA commissioner Scott Gottlieb.
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
Top official unconcerned by dip in approval rate. The departure of Scott Gottlieb in April robbed the FDA of one of its most dynamic ever Commissioners, and industry observers have been ... Before Gottlieb departed earlier this year, he unveiled a new
-
Ex-FDA chief Gottlieb's quick move to pharma raises eyebrows
Will join Pfizer board. Just 83 days after leaving his Commissioner role at the FDA, Scott Gottlieb has joined the board of big pharma group Pfizer. ... We are fortunate to have D. Gottlieb join Pfizer’s Board of Directors,” said Pfizer executive
-
Verily unveils next-gen trials alliance with Novartis, Pfizer
There is also no doubt that regulators are keen to see the industry update its practices. Shortly before he stepped down as FDA commissioner earlier this year, Scott Gottlieb expressed his
More from news
Approximately 5 fully matching, plus 45 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
He replaced Scott Gottlieb, who was popular with industry but resigned from the post unexpectedly last year, as well as stand-in Ned Sharpless who has now returned to his post
-
Will biosimilars ever catch on in the US?
In the early days of the Trump administration, then-FDA commissioner Scott Gottlieb made a point of clearing the way for even faster and more generic approvals, again with some apparent ... Based on those assumed savings, had all the FDA-approved
-
Encouraging signs in biomarker R&D
The timing of the withdrawal was ironic given that, in the same month, FDA Commissioner Scott Gottlieb highlighted ‘TMB as a potential biomarker for enriching clinical trials testing immunotherapies’. ... Harmonisation. Gottlieb has since resigned,
-
Streamlining clinical trials – why better data use is key
Dr Scott Gottlieb’s brief, energetic tenure as US FDA Commissioner is likely to shape agency oversight of the pharmaceutical industry for years to come, particularly in relation to clinical development. ... To embrace innovations like blockchain, as
-
Cell and gene therapy
Interest in cell and gene therapies is undeniable. In January, US FDA Commissioner Scott Gottlieb outlined policies designed to accommodate an anticipated surge in cell and gene therapy submissions. ... Gottlieb highlighted manufacture as a challenge
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- Moderna CEO says COVID-19 vaccine will be ready for FDA submission in late November
- The Truth about Doctors
- Lilly buys biotech firm Disarm Therapeutics for $135m
- UK scientists begin testing BCG vaccine for severe COVID-19 protection
- How will the events and exhibitions industry change post-Coronavirus?
- How community outreach can help improve diversity in clinical research
- Neurofibromatosis: a condition that’s hard to say, but even harder to live with
- Do you know what PoTS is?
- St John & St Elizabeth Hospital “Putting people first” by Seven Stones
- OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
- Moderna’s chief exec expects to have COVID-19 vaccine data in November
PMHub
Bedrock Group
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- How community outreach can help improve diversity in clinical research
- To execute a considered community engagement strategy, an involved and collaborative process is needed....
- OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
- ...
- Can eLearning improve patient recruitment and retention?
- Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
Quick links
Infographics
